ViiV found by GSK (GSK) and Pfizer (PFE) are in focus as its long acting HIV PrEP therapy cabotegravir outperforms Gilead's lenacapavir in Phase 1 trial. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback